Melanie Greenway, PA
Physician Assistant · Baltimore, MDNPI 1598195604
Payments from drug & device makers
Across 606 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Pfizer$1K
- Lilly USA, LLC$794
- Amgen$751
- Astellas Pharma US Inc$544
- plus $4K from 36 others
What the payments were for
- Food & beverage$9,888100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,517 |
| Novo Nordisk | 65 | $1,099 |
| Pfizer | 66 | $1,007 |
| Lilly USA, LLC | 51 | $794 |
| Amgen | 44 | $751 |
| Astellas Pharma US Inc | 27 | $544 |
| GSK | 23 | $442 |
| Biohaven Pharmaceutical Holding Company Ltd. | 30 | $427 |
| Boehringer Ingelheim | 21 | $421 |
| Amarin Pharma, Inc. | 18 | $336 |
| AstraZeneca | 15 | $312 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $312 |
| Esperion Therapeutics, Inc. | 17 | $220 |
| Biohaven Pharmaceuticals, Inc. | 11 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $175 |
| Johnson & Johnson | 9 | $146 |
| E.r. Squibb & Sons, L.L.C. | 7 | $143 |
| Merck | 8 | $123 |
| Novartis | 7 | $120 |
| Eisai Inc. | 6 | $104 |
| Lundbeck LLC | 4 | $97 |
| Antares Pharma, Inc. | 5 | $90 |
| Bayer | 3 | $73 |
| Abbott | 3 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Halozyme Inc | 2 | $34 |
| Nevro Corp. | 2 | $32 |
| Seqirus USA Inc | 2 | $30 |
| Neurelis, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $27 |
| Bausch Health US, LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $21 |
| Insightec,inc | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Medtronic | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Vertex | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
How this compares
$9,888 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $41,238 |
| TrulicityDulaglutide | 17 | $37,376 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $33,375 |
| JardianceEmpagliflozin | 14 | $21,967 |
| JanuviaSitagliptin Phosphate | 13 | $21,538 |
| EliquisApixaban | 16 | $20,936 |
| FarxigaDapagliflozin Propanediol | 11 | $18,275 |
| MounjaroTirzepatide | 11 | $17,686 |
| OzempicSemaglutide | 13 | $13,041 |
| Ezetimibe | 43 | $3,496 |
| Atorvastatin Calcium | 251 | $3,430 |
| SynthroidLevothyroxine Sodium | 21 | $2,012 |
| Nebivolol Hcl | 20 | $1,724 |
| Ibandronate Sodium | 18 | $1,633 |
| Levothyroxine Sodium | 196 | $1,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $794 | $55,06228 claims |
| Johnson & JohnsonXarelto | $146 | $41,23826 claims |
| GSKTrelegy Ellipta | $442 | $33,37528 claims |
| Boehringer IngelheimJardiance | $421 | $21,96714 claims |
| MerckJanuvia | $123 | $21,53813 claims |
| PfizerEliquis | $1,007 | $20,93616 claims |
| AstraZenecaFarxiga | $312 | $18,27511 claims |
| Novo NordiskOzempic | $1,099 | $13,04113 claims |
| AbbVieSynthroid | $1,517 | $2,01221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Baltimore
- Kara CossisBaltimore$177K
- Melissa BearekmanBaltimore$81K
- Bruce SmithBaltimore$63K
- Shannon MarriottBaltimore$38K
- Praveena GadamBaltimore$24K
- James ShafferBaltimore$12K
- Joyce FreidlyBaltimore$10K
- Maria RosenbergBaltimore$10K
- Thomas PetryBaltimore$10K
- Margaret JoyceTowson$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.